Overview

Study of CYR-101 in Patients With Schizophrenia

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This Phase II study will test whether CYR-101, a CNS-active compound with novel pharmacological profile and devoid of dopamine D2 receptor binding properties, is efficacious when administered orally in the management of patients with a diagnosis of DSM-IV schizophrenia.
Phase:
Phase 2
Details
Lead Sponsor:
Cyrenaic Pharmaceuticals